CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
CorMedix Therapeutics (Nasdaq: CRMD) will report third-quarter 2026 financial results before the market opens on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CorMedix Therapeutics (Nasdaq: CRMD) will report third-quarter 2026 financial results before the market opens on November 12, 2026. The results cover the quarter ended September 30, 2026. A corporate update conference call will follow at 8:30 a.m. Eastern Standard Time that day.
Key Figures
- Results date
- November 12, 2026
- Third-quarter 2026 financial results scheduled before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.
| Thursday, November 12th at 8:30 a.m. EST | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
